Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource

Documenti analoghi

• Cost‐effectiveness of sutimlimab in cold agglutinin disease
  di: Satoko Ito, et al.
  Pubblicazione: (2024)
• Cost‐Effectiveness of Ferritin Screening Thresholds for Iron Deficiency in Reproductive‐Age Women
  di: Daniel Wang, et al.
  Pubblicazione: (2025)
• Associations between blood donors, component modifications, and the alloimmunization of transfusion recipients
  di: Han Yu, et al.
  Pubblicazione: (2025)
• Long‐term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial
  di: Mary Eapen, et al.
  Pubblicazione: (2024)
• JAKPOT Prediction Rule for Erythrocytosis: External Validation and Cost‐Effectiveness Analysis
  di: Barbara D. Lam, et al.
  Pubblicazione: (2026)